Literature DB >> 389413

Acute myeloblastic leukemia developing in patients with mediastinal lymphoblastic lymphoma.

C R Kjeldsberg, B N Nathwani, H Rappaport.   

Abstract

Of three patients with mediastinal malignant lymphoma, lymphoblastic type, at the time of diagnosis one also had acute myeloblastic leukemia (AML), and the other two had blood and bone marrow findings indicative of acute lymphoblastic leukemia (ALL). The latter two patients developed the hematologic picture of AML less than eight months later. In all cases, AML was confirmed by cytochemical studies of peripheral blood and bone marrow cells. Autopsy of two of the patients revealed only AML. The myeloid nature of the proliferative cells was demonstrated with the naphthol-ASD-chloroacetate stain (NCA) on postmortem tissue sections. This study further supports the hypothesis of a common origin of neoplastic lymphoid and myeloid cells from pluripotent bone marrow stem cells.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 389413     DOI: 10.1002/1097-0142(197912)44:6<2316::aid-cncr2820440647>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Granulocytic sarcoma: misleading immunohistological staining with MT1 and S100 protein antibodies.

Authors:  C J Elliott; K P McCarthy; R L Carter; P Davies
Journal:  J Clin Pathol       Date:  1989-02       Impact factor: 3.411

2.  Coexistence of Trisomy 8 and 13 in a Newly Diagnosed Patient With Diffuse Large B Cell Non-Hodgkin Lymphoma and Acute Myeloid Leukemia Secondary to Primary Myelofibrosis.

Authors:  Horia Bumbea; Viola Maria Popov; Ciprian Tomuleasa; Meilin Omer; Camelia Dobrea; Irina Manea; Sabina Zurac; Cristiana Popp; Ion Dumitru; Madalina Simoiu; Bogdan Mastalier
Journal:  Cureus       Date:  2022-02-14

3.  Phenotypic conversion of T lymphoblastic lymphoma to acute biphenotypic leukemia composed of lymphoblasts and myeloblasts. Molecular genetic evidence of the same clonal origin.

Authors:  T Nosaka; H Ohno; S Doi; S Fukuhara; H Miwa; K Kita; S Shirakawa; T Honjo; M Hatanaka
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.